Jinning Gao

Title: Innovations in Lung Adenocarcinoma Treatment by Jinning Gao

Introduction

Jinning Gao is a prominent inventor based in Qingdao, China. He has made significant contributions to the field of biomedical technology, particularly in the development of targeted therapeutic drugs for cancer treatment. His innovative work focuses on the use of PIWI-interacting RNA, which has the potential to revolutionize the approach to lung adenocarcinoma therapy.

Latest Patents

Jinning Gao holds a patent for the use of PIWI-interacting RNA piR-hsa-211106. This invention is designed to prepare a targeted therapeutic drug aimed at inhibiting the proliferation of lung adenocarcinoma cells. The mechanism involves constructing the PIWI-interacting RNA piR-hsa-211106 into an agonist or a transformant. This agonist or transformant inhibits the tricarboxylic acid cycle process by down-regulating the expression of pyruvate carboxylase. Consequently, it inhibits energy metabolism and promotes apoptosis in lung adenocarcinoma cells, effectively inhibiting their growth. Notably, the PIWI-interacting RNA piR-hsa-211106 directly targets the site of action without producing toxic side effects or off-target phenomena. Extensive analyses and both in-vivo and in-vitro experiments have demonstrated the high credibility and remarkable treatment effects of this innovation, providing a new research direction for anti-tumor therapy in lung adenocarcinoma.

Career Highlights

Throughout his career, Jinning Gao has focused on advancing cancer treatment methodologies. His dedication to research and innovation has led to significant breakthroughs in understanding the mechanisms of lung adenocarcinoma. His work is characterized by a commitment to developing effective and safe therapeutic options for patients.

Collaborations

Jinning Gao has collaborated with notable colleagues, including Wenhua Xu and Yongmei Liu. These partnerships have enhanced the research and development process, contributing to the success of his innovative projects.

Conclusion

Jinning Gao's contributions to the field of biomedical technology, particularly through his patent on PIWI-interacting RNA piR-hsa-211106, represent a significant advancement in the treatment of lung adenocarcinoma. His work not only showcases the potential of targeted therapies but also opens new avenues for future research in cancer treatment.